Etoposide (Synonyms: VP-16; VP-16-213) |
Catalog No.GC15617
One-Click Copy Product Info
|
Etoposide (VP-16) is a nonspecific inhibitor of topoisomerase II with an IC50 value of 59.2μM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 33419-42-0
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Etoposide (VP-16) is a nonspecific inhibitor of topoisomerase II with an IC50 value of 59.2μM[1]. Etoposide inhibits DNA synthesis by inhibiting topoisomerase II activity, and can induce cell cycle arrest, apoptosis, and autophagy[2].
In vitro, treatment of HCT116 FBXW7+/+, FBXW7−/−, and p53−/− cells with Etoposide (0-1μM) for 72h inhibited cell growth in a dose-dependent manner with IC50 values of 0.945μM, 0.375μM, and 1.437μM, respectively[3]. Treatment of adherent C33a cells with Etoposide (5μM) for 48h induced marginal cell apoptosis and cell cycle G2/M arrest[4].
In vivo, Etoposide (80mg/kg) was injected intraperitoneally into adult Smc5 flox/del, Stra8-Cre cKO mice. After 8 days of exposure, spermatocyte defects were observed in the mice, with an increase in the number of enlarged round spermatids with two acrosomes and extra chromosomes [5]. Etoposide (50mg/kg) was injected intraperitoneally into mice inoculated with 3LL lung cancer cells, inducing the host immune system to recognize 3LL cells and increasing the survival rate of the mice to 60% [6].
References:
[1] Sudo K, Konno K, Shigeta S, et al. Inhibitory effects of podophyllotoxin derivatives on herpes simplex virus replication[J]. Antiviral Chemistry and Chemotherapy, 1998, 9(3): 263-267.
[2] Xu D, Cao J, Qian S, et al. 5k, a novel β-O-demethyl-epipodophyllotoxin analogue, inhibits the proliferation of cancer cells in vitro and in vivo via the induction of G2 arrest and apoptosis[J]. Investigational new drugs, 2011, 29: 786-799.
[3] Cui D, Xiong X, Shu J, et al. FBXW7 confers radiation survival by targeting p53 for degradation[J]. Cell reports, 2020, 30(2): 497-509. e4.
[4] Bristol M L, Wang X, Smith N W, et al. DNA damage reduces the quality, but not the quantity of human papillomavirus 16 E1 and E2 DNA replication[J]. Viruses, 2016, 8(6): 175.
[5] Hwang G, Verver D E, Handel M A, et al. Depletion of SMC5/6 sensitizes male germ cells to DNA damage[J]. Molecular biology of the cell, 2018, 29(25): 3003-3016.
[6] Slater L M, Stupecky M, Sweet P, et al. Etoposide induction of tumor immunity in Lewis lung cancer[J]. Cancer chemotherapy and pharmacology, 2001, 48: 327-332.
| Cell experiment [1]: | |
|
Cell lines |
HCT116 FBXW7+/+, FBXW7−/−, p53−/− cells |
|
Preparation Method |
HCT116 FBXW7+/+, FBXW7−/− and p53−/− cells were seeded in 96-well plates at 2×103 cells per well in triplicate. Cells were treated with etoposide at 0-1μM for 72 h. |
|
Reaction Conditions |
0-1μM; 72h |
|
Applications |
Etoposide inhibited HCT116 FBXW+/+, FBXW-/-, and p53-/- in a dose-dependent manner with IC50 of 0.945 μM, 0.375 μM, and 1.437 μM, respectively. |
| Animal experiment [2]: | |
|
Animal models |
Adult Smc5 flox/del, Stra8-Cre cKO mice |
|
Preparation Method |
Adult Smc5 flox/del, Stra8-Cre cKO and control mice were injected intraperitoneally with a single dose of etoposide (80mg/kg body weight). After injection, the mice were monitored daily before being killed at 3, 5, or 8 d after treatment. |
|
Dosage form |
80mg/kg; i.p. |
|
Applications |
Following 8d of etoposide exposure, an increase in the number of enlarged spermatids, often with two acrosomes, was observed in the Smc5 flox/del, Stra8-Cre cKO. |
|
References: |
|
| Cas No. | 33419-42-0 | SDF | |
| Synonyms | VP-16; VP-16-213 | ||
| Chemical Name | (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one | ||
| Canonical SMILES | CC1OCC2C(O1)C(C(C(O2)OC3C4COC(=O)C4C(C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O | ||
| Formula | C29H32O13 | M.Wt | 588.56 |
| Solubility | ≥ 29.45mg/mL in DMSO | Storage | -20°C, protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.6991 mL | 8.4953 mL | 16.9906 mL |
| 5 mM | 339.8 μL | 1.6991 mL | 3.3981 mL |
| 10 mM | 169.9 μL | 849.5 μL | 1.6991 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 15 reference(s) in Google Scholar.)